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Sarcomas are a group of heterogeneous tumours with varying genetic basis. Cytogenetic abnormalities range from distinct
genomic rearrangements such as pathognomonic translocation events and common chromosomal ampliﬁcation or loss, to more
complex rearrangements involving multiple chromosomes. The diﬀerent subtypes of liposarcoma are spread across this spectrum
and constitute an interesting tumour type for molecular review. This paper will outline molecular pathogenesis of the three
main subtypes of liposarcoma: well-diﬀerentiated/dediﬀerentiated, myxoid/round cell, and pleomorphic liposarcoma. Both the
molecular basis and future avenues for therapeutic intervention will be discussed.
1.Introduction
An estimated 13,000 people were diagnosed with soft tissue
andbonesarcomain2009inAmerica,ofwhichliposarcomas
constitute20%[1,2].Despitetheirrarity thesetumourshave
substantial morbidity and mortality, depending on histolog-
ical subtype, tumour location, and volume with retroperi-
toneal sarcomas having particularly poor prognosis [3–9].
Liposarcomas may be classiﬁed morphologically into 3 main
subtypes consisting of: well-diﬀerentiated liposarcoma/de-
diﬀerentiated liposarcoma (WD/DDLPS), myxoid/round
cell liposarcoma (MLPS) and pleomorphic liposarcoma
(PLPS) [10]. The morphological diversity of liposarcoma
reﬂects the great variation in biological behaviour ranging
from tumours with lowmetastatic potential, thatis, WDLPS,
to tumours with high propensity to metastasise, that is, the
round cell (RC) variant of MLPS or PLPS [11]. In addition
to histological characteristics, anatomical location impacts
upon prognosis, given that local control is a prime concern
for curative intent.
Treatment is multimodal with surgical removal and ra-
diotherapy used as cornerstones for local control, along
with chemotherapy for systemic disease. Few therapeutic
options are available for aggressive local or metastatic dis-
ease. Chemotherapy sensitivity varies considerably between
subtypes with higher response rates in MLPS compared with
WD/DDLPS (48% versus 11%) [12]. MLPS tumours are
also highly radiosensitive [13, 14]. Given the small subgroup
that is chemo-sensitive, and the overriding lack of chemo-
curative disease there are avenues and a need for novel
molecular therapies.
A recent histological and molecular review of 163 lipo-
sarcoma and lipomas at the Netherlands Cancer Institute
resulted in 23% of tumours being reclassiﬁed based on
cytogenetic information. This highlights the importance
of molecular classiﬁcation in these tumours and genetic
alterations now consideredan integral part of theWHO clas-
siﬁcation [15]. It is hoped that further insight into the
molecular characteristics of liposarcomas will allow for
accurate subclassiﬁcation, whilst providing a platform for
molecular therapies to be included in the current treatment
approach. This paper will outline the current molecular
basis of liposarcoma and potential strategies for therapeutic
intervention.
2.Well- andDe-differentiatedLiposarcoma
WDLPS represents 40%–45% of all diagnosis of liposarcoma
[16]. It is classiﬁed as a low-grade neoplasm; it is rarely
metastatic and has a low recurrence rate (10%) occurring
most often in the retroperitoneum and limbs. The World2 Sarcoma
Health Organization (WHO) classiﬁes WDLPS into three
main subtypes: adipocytic, sclerosing, and inﬂammatory.
Adipocytic(lipoma-like)liposarcomaiscomposedofmature
adipocytes, which exhibit variation in cell size and focal
nuclear atypia and hyperchromasia [16]. The sclerosing
subtype shows scattered distinctive bizarre stromal cells
associated with rare multivacuolated lipoblasts set in a ﬁbril-
lary collagenous background [16]. Finally, the inﬂammatory
subtypeshowspolyphenotypiclymphoplasmacyticinﬁltrate,
with a B-cell predominance. Less is known about this rare
subtype [16–18].
DDLPS represents progression from low grade to high-
grade nonlipogenic morphology within a WDLPS. DDLPS
is more aggressive and exhibits an increased rapidity of
disease in contrast to WDLPS, with a metastatic rate of
10%–20% and overall mortality of 50%–75% [4, 7, 19].
In respect to tumour site, retroperitoneal tumours appear
to have a worse prognosis [19]. Histologically, DDLPS
consists of a WDPLS with a nonlipogenic component,
either high-grade, most often resembling malignant ﬁbrous
histiocytoma (MFH), or low-grade resembling ﬁbromatosis
or low-grade myxoﬁbrosarcoma. The presence of transition
from WDLPS to DDLPS is used to diﬀerentiate between
DDLPS and these other lesions [4, 7, 11, 19–21].
2.1. Molecular Genetics. A characteristic feature of
WD/DDLPS is the presence of supernumerary ring
and/or giant rod chromosomes [22]. These chromosomes
contain ampliﬁed segments from the 12q13–15 region that
can be identiﬁed with ﬂuorescence in situ hybridization
(FISH) and comparative genomic hybridization (CGH)
[23]. Intensive research has identiﬁed several oncogenes
residing in this region including MDM2, CDK4, HMGA2,
TSPAN31,OS1,OS9, CHOP and GLI1[11,23–25]. The most
compelling evidence to date demonstrates an oncogenic
role in WD/DDLPS for MDM2, CDK4, HMGA2 and
TSPAN31. Additional ampliﬁcation events may also play
a role in liposarcoma genesis, for example, c-Jun in the
de-diﬀerentiation process [26].
MDM2 ampliﬁcation is a key feature of WD/DDLPS
and is ampliﬁed and overexpressed in a number of other
cancers, highlighting its importance in tumorigenesis (as
reviewed [27]). MDM2 encodes a negative regulator of the
tumour suppressor, p53. MDM2 binds to the transcription
activationdomainofp53,withinanN-terminalhydrophobic
pocket [28], blocking p53-dependent transcription [29–33]
and recruitment of transcription coactivators [28]. MDM2
also acts as a ubiquitin ligase targeting p53 for protea-
somal degradation through both cytoplasmic and nuclear
proteasomes [34–36]. MDM2 is involved in its own auto-
degradationtopreventMDM2activityinhibiting p53during
times of cellular stress [37]. Thus MDM2 maintains tight
control on cellular p53 levels through multiple mechanisms
(see Figure 1)[ 38, 39]. Therapeutically this is important,
as MDM2 inhibitors aim to reactivate p53 and thus allow
it to actively induce cell death in response to appropriate
stressors [40]. In addition to a functional downstream p53
signalling pathway, MDM2 ampliﬁcation is a predictor of
sensitivity to current MDM2 antagonists [40]. Ampliﬁcation
of MDM2 and mutation of p53 appear to be mutually exclu-
sive events in WDLPS, but have been reported in DDLPS
[41, 42]. p53 mutations have been associated with the de-
diﬀerentiation process from WDLPS to DDLPS [41]. Pilotti
et al. reported upon a subgroup of WD/DDLPS tumours.
RetroperitonealWD/DDLPSdemonstratemutualexclusivity
between MDM2 ampliﬁcation and p53 mutation. In non-
retroperitoneal DDLPS, p53 mutations occur in the absence
of MDM2 ampliﬁcation suggesting involvement in the de-
diﬀerentiation process [41].
MDM2 is the most frequent ampliﬁcation in WD/
DDLPS (close to 100%) however CDK4 is shown to be
ampliﬁed in over 90% of cases [16, 43, 44]. Given its
role in the cell cycle and the frequency of ampliﬁcation,
CDK4 has been well researched in WD/DDLPS. The CDK4
gene encodes a 33-kD protein that forms complexes with
the cyclin D family, to enable G1-S transition [45]. These
CDK4/Cyclin D complexes phosphorylate pRb (encoded by
RB1), with resultant activation of E2F target genes including
E-type cyclins (see Figure 2)[ 46–48]. It has been suggested
that CDK4 provides a selection advantage in WD/DDLPS
and may contribute to transformation as CDK4 negative
WDLPS exhibit more favorable prognostic features [46].
Coampliﬁcation of MDM2 and CDK4 is a common feature
ofWD/DDLPSand may result in proliferation through com-
bined eﬀects upon p53 and the cell cycle [49, 50]. Interest-
ingly,therearrangementsofchromosome12onthegiantrod
chromosome are discontinuous and MDM2 and CDK4 may
belong to diﬀerent amplicons [51, 52]. Several studies [43,
53, 54] have suggested that immunohistochemical staining
for both CDK4 and MDM2 may provide a useful diagnostic
marker, although FISH and quantitative polymerase chain
reaction (qPCR) are more eﬀective. Although MDM2 and
CDK4 are useful markers to aid in diagnosis, overexpression
of these markers is not unique to WD/DDLPS [43, 54].
Further, the ampliﬁcation and over-expression of CDK4 and
MDM2 does not distinguish WDLPS from DDLPS [16, 23,
41].
HMGA2issimilarly locatedon12qandfrequentlyampli-
ﬁed in WD/DDLPS. This is a member of the high-mobility
group of proteins [55, 56]. Previously referred to as HMGIC,
it encodes an architectural transcription factor capable of
remodeling DNA [57–59]. A direct role for HMGA2 in cel-
lular transformation is demonstrated by NIH3T3 neoplastic
transformation with the overexpression of HMGA2 [60].
In human sarcomas during chromosomal rearrangement,
HMGA2 is fused to distant sequences, commonly occurring
on other chromosomes and loses its 3  translated end
that also contains sites for Let-7 microRNAS [57]. Further
support for HMGA2 involvement in adipogenic neoplasm
development includes the xenograft model by Arlotta et
al. [55] that showed mice expressing C-terminal trun-
cated HMGA2 developed lipomas. Interestingly HMGA2 is
frequently coampliﬁed with MDM2 in human malignant
tumours [57, 61], particularly WDLPS and DDLPS [52].
This raises the possibility that HMGA2 and MDM2 have
a cooperating role in WD/DDLPS. Also included within
the chromosome 12q13–15 region is the transmembraneSarcoma 3
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Figure 1: MDM2 binds to the transcriptional activation domain of p53, blocking transcription. MDM2 fun c t i o n sa sau b i q u i t i nl i g a s e ,
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Figure 2: Cyclin dependent kinase CDK4 binds with cyclin D to
form active complexes. This results in phosphorylation of Rb and
dissociates pRb from the pRb-E2F complex. E2F binds DNA to
upregulate transcription of genes required to progress to S phase.
superfamily gene, sarcoma ampliﬁed sequence (SAS or
TSPAN31)g e n e[ 62, 63]. TSPAN31 was originally identiﬁed
and cloned from an ampliﬁed sequence in a malignant
ﬁbroushistiocytoma[63].Ithasbeenidentiﬁedinothersub-
types of sarcoma, particularly de-diﬀerentiated liposarcoma
[64, 65], although its precise role in the de-diﬀerentiation
process is not well delineated. Forus et al. [66]s h o w e d
TSPAN31 was as frequently ampliﬁed as MDM2 in 98
sarcomas. Both TSPAN31 and MDM2 were ampliﬁed in 8
of 11 liposarcoma samples, with MDM2 ampliﬁed alone in
one additional tumour. WDLPS and DDLPS have shown
co-ampliﬁcation of 1q21-q22 and/or 12q21-q22 [11, 16,
23], along with ampliﬁcation of chromosome 1(1q21-q23).
Chromosome 1 ampliﬁed sequences include COAS1, COAS2
and COAS3 [67]. Nilsson et al. showed co-ampliﬁcation of
both COAS and MDM2 in 12/18 lipomatous tumours [68].
The biological function of the COAS genes remains a subject
for study.
Recent studies into the WDLPS de-diﬀerentiation pro-
cess have suggested a role for the c-Jun N-terminal kinase
(JNK) pathway. Co-ampliﬁcation of 1p32 and 6q23, that
contain c-Jun, and Apoptosis Signaling Kinase 1 (ASK1), are
seen in DDLPS but not WDLPS [69]. The proto-oncogene
c-Jun encodes part of the activator protein transcription
factor (AP-1) complex involved in cell proliferation, trans-
formation and apoptosis [70]. ASK1 activates JNK [71, 72]
ultimately leading to c-Jun activation and PPARγ inacti-
vation. PPARγ is involved in the adipocytic diﬀerentiation
process and its inhibition may result in de-diﬀerentiation.
A further role for c-Jun in the de-diﬀerentiation process
is demonstrated by overexpression in a 3T3-L1 adipocytic
tumour xenograft model. Transfection of c-Jun into 3T3-L1
cells in vitro delays adipocytic diﬀerentiation [26].
3.Myxoid Liposarcoma
MLPS is the second most common subtype of liposarcoma
and accounts for more than one third of liposarcomas and
10% of all adult soft tissue sarcomas. MLPS is characterized
by the presence of spindle or ovoid cells set in a myxoid
stroma with signet ring lipoblasts and a distinctive chicken-
wire pattern vasculature. The presence of areas with greater
cellularity, known as round cell (RC) de-diﬀerentiation,
is associated with a worse prognosis [73]. Unusual sites
of metastasis are common in MLPS with a propensity
to metastasize to soft tissue and bone rather than lung
[74, 75]. Thirty-one percent of MLPS patients develop
metastasis with bone metastases constituting 56% of these
[74].MLPS exhibits inferior survival comparedto other low-
grade sarcoma subtypes with a 5-year disease survival rate of
85%[76,77].MLPSwithoutRCisparticularlyradiosensitive
with good local control rates with patients treated with
adjuvant or neoadjuvant radiotherapy approaching 98% 5-
year local control [13, 78].
3.1. Molecular Genetics. MLPS is characterised by the recur-
rent translocation t(12;16)(q13;p11) that results in the FUS-
CHOP gene fusion that is present in over 95% of cases
[79, 80]. In most cases, the amino terminal domain of FUS
(also known as TLS) is fused to C/EBP homologous protein
(CHOP,a l s ok n o w na sDDIT3 or GADD153). In rare cases,
an alternative translocation event is found t(12;22)(q13;q12)
that results in formation of the novel fusion oncogene where
EWS takesthe place ofFUS [81, 82]. There is strong evidence
for these translocations to be the primary oncogenic eventin4 Sarcoma
MLPS as these tumours have a relatively normal karyotype,
the exception being a few recurrent cases of trisomy 8
[83]. In addition, several growth factor pathways have been
implicated in MLPS pathogenesis [84–86].
There are currently 11 diﬀerent FUS-CHOP chimeras
and 4 diﬀerentknown EWS-CHOP fusion genes. In the most
common variants, a portion of the amino terminus of FUS
is fused to the entire coding region of CHOP.T h eFUS-
CHOP transcript type does not appear to have a signiﬁcant
impact upon clinical outcome, and RC content, necrosis
and p53 expression remain stronger predictors of clinical
outcome[79,87].There isevidencethatthefusiontranscript
type may inﬂuence response to therapy although the studies
are hindered by sample size [88–90]. Understanding how
the FUS-CHOP fusion causes MLPS and uncovering any
further molecular abnormalities in the disease will aid in
development of novel targeted therapies.
FUS belongs to the FET family of RNA-binding proteins
that consists of FUS, EWS, and TAF15 as well as the closely
homologous, Drosophila SARFH (Cab) [80, 91, 92]. These
structurally and functionally related RNA-binding proteins
are composed of an SYGQ-rich amino terminus, an RNA
recognition motif, a zinc ﬁnger motif, and at least one RGG
rich repeat region [93, 94]. FET proteins are expressed in
most human tissues and appear to be regulated following
diﬀerentiation in neuroblastoma cells and spontaneously
diﬀerentiating human embryonic stem cells [95].
Both FUS and EWS have been shown to localize to the
nucleus and the cytoplasm, bind RNA, and are also involved
in nucleo-cytoplasmic shuttling [96–98]. The FET family
associate with various complexes involved in the induction
of transcription, including RNA polymerase II (RNAPII),
which regulates transcription and TFIID complexes, that
binds DNA as part of the transcriptional machinery [91],
implicating both FUS and EWS in transcriptional control.
In addition, FUS has recently been shown to repress
transcriptionofRNApolymerase III(RNAPIII),suggestinga
broader role in regulation through multiple diﬀerent mech-
anisms [99]. Noncoding RNAs are capable of allosterically
modifying FUS in response to DNA damage to inhibit the
transcription factor CREB-binding protein (CBP) and p300
histone acetyltransferase activity, resulting in transcriptional
inhibition at the cyclin D1 promoter in cell lines and shows
a further role for FUS in transcriptional control [100]. FUS
has also been implicated in the DNA damage response as a
downstream target of ATM, which can detect and coordinate
DNA repair [101].
CHOP is induced in response to endoplasmic reticular
stress and is involved in mediating cell death in response to
suchstressstimuli[102].CHOPalsoplaysaroleinregulating
diﬀerentiation in adipocytes by interfering with the process
in response to metabolic stress [103]. Adipocytic diﬀeren-
tiation is dependent on the coordinated expression of a
groupoftranscriptionfactors,theCCAAT/enhancer-binding
protein (C/EBP) family of proteins [104]. The C/EBP family
consists of six members from C/EBPα to ζ,a n dt h e yr e q u i r e
dimerisation to bind DNA and can form homodimers or
heterodimers. CHOP is capable of binding to the C/EBP
family members through their highly conserved leucine
zipper domain and inhibiting their function. The leucine
zipper dimerization domain and the adjacent basic region
in CHOP are required for NIH-3T3 transformation with
FUS-CHOP, highlighting the requirement for functional
DNA binding and dimerization for FUS-CHOP induced
oncogenesis [105].
As C/EBPα and C/EBPβ play an important role in
the adipogenic diﬀerentiation and are regulated by CHOP,
it is possible FUS-CHOP may interfere in cellular diﬀer-
entiation. In support, various studies suggest that FUS-
CHOPfunctions byinhibiting adipogenesis andmaintaining
immature adipocytes in a continuous cycle of proliferation
without diﬀerentiation [106–108]. Introduction of FUS-
CHOP into mice, where expression of the transgene is
driven by the ubiquitously expressed elongation factor 1α
(EF1α) promoter, results speciﬁcally in liposarcomas with
inherent induction of adipocyte speciﬁc genes such as
PPARγ [109]. Further evidence of adipogenic diﬀerentiation
block resulting from FUS-CHOP expression was shown in
vitro where mice expressing FUS-CHOP under the control
of the aP2 promoter, which is a downstream target of
PPARγ expressed in immature adipocytes, failed to develop
liposarcomas, indicating interference between PPARγ and
aP2 activation [107].
An emerging clinically relevant targetable pathway in
MLPS involves the receptor tyrosine kinases (RTKs) MET,
RET, and the PI3K signaling cascade (see Figure 3). RET is
overexpressed in MLPS compared to normal fat [84]a n d
high expression has been correlated with poor metastasis
free survival in MLPS [108]. RET, IGF1R and IGF2 are
highly expressed in MLPS and promote cell survival through
both the PI3K/Akt and Ras-Raf-ERK/MAPK pathways [85,
86]. A panel of tyrosine kinases including PDGFRB, EGFR,
MET, RET, and VEGFR2 are activated in both treated (with
chemotherapy/radiotherapy or Trabectedin) and untreated
cases of human MLPS [110]. In addition to activation of
MET in clinical MLPS specimens, MET and the ligand HGF
are potentially regulated by FUS-CHOP. Both MET and
HGF are highly expressed in mesenchymal progenitor cells
transfected withFUS-CHOPinadisease mimickingallograft
mouse model [111]. In a small clinical cohort, speciﬁc Akt
phosphorylation was observed in the RC variant and 2
treated cases that harboured PTEN mutations, implicating
RTK pathways signaling through Akt in MLPS [110]. FLT1
(that encodes the VEGFR1 protein) is expressed as an
indirect downstreameﬀectof FUS-CHOPexpression inboth
FUS-CHOP transfected HT1080 (ﬁbrosarcoma) and MLPS
cell lines however, VEGFR tyrosine kinase inhibitors did not
have a notable impact on proliferation in MLPS cell lines
indicating a separate role in these cells [112, 113].
Akt activation, particularly in the RC variant, suggests
a role for phosphoinositide 3-kinases (PI3K) [110]. PI3Ks
are activated upon phosphorylation of membrane bound
receptor tyrosine kinases. PI3K can activate many proteins
including the protein serine-threonine kinase Akt, which
when phosphorylated causes downstream activation and
ultimately cell growth, cell cycle entry, and subsequently
survival.ThePI3Kholoenzymecomplexiscomposedofboth
a catalytic and regulatory subunit. The catalytic subunit,Sarcoma 5
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Figure 3: The PI3K pathway is highly active in MLPS, and this is potentiated at least in part by overexpression, and/or activation through
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PIK3CA and PTEN mutations and Akt activation have also been documented in MLPS.
PIK3CA, encodes the p110α isoform and is commonly
mutated in various cancer types including breast, colon,
brain and gastric malignancies [114, 115]. A recent study
showed 18% of MLPS patients (n = 71) had PIK3CA
mutations in either the helical (E542K and E545K) or
kinase (H1047L and H1047R) domain. The presence of a
PIK3CA mutation was associated with a shortened disease
speciﬁc survival [116]. Barretina et al. also showed one
tumour with a homozygous PTEN mutation. PTEN is a
tumour suppressor that dephosphorylates phosphoinositide
substrates to negatively regulate the Akt signaling pathway
[117], demonstrating more mechanisms for perturbation of
the pathway.
4.PleomorphicLiposarcoma
PLPS accounts for only 5% of liposarcomas and occurs
mainly within the 55–65 year-old group [8, 118, 119]. PLPS
mortality is 40% with no current clinical or pathological
predictors of outcome [8, 120]. Histologically PLPS are
similar to MFH with the addition of lipoblasts. Histology
reveals a disorderly growth pattern, extreme cellularity, and
cellular pleomorphism including bizarre giant cells [121].
Lesional cells are polygonal with pale eosinophilic cytoplasm
and poorly demarcated boundaries. These lesional cells are
interspersed with giant lipoblasts containing enlarged hyper-
chromatic, angular or globular nuclei [121, 122].
4.1. Molecular Genetics. Molecular studies of PLPS are
limited by the scarcity of this disease. Tumours tend to show
complex arrangements including gains: 1p, 1q21-q32,2q, 3p,
3q, 5p12-p15, 5q, 6p21, 7p, 7q22 (see reviews) [118, 123,
124]. reported literature shows losses i of 1q, 2q, 3p, 4q,
10q, 11q, 12p13, 13q14, 13q21-qter, 13q23-24, (see reviews)
[123–125], Taylor et al. described that 60% of PLPS have a
deletion of 13q14.2-q14.3, a region that includes the tumour
suppressor RB1 [123]. Also ampliﬁed in PLPS, the mitotic
arrest deﬁcient (MAD2) may also play a critical role [126,
127]. As reported by Singer et al. [126], MAD2 was found
to be over-expressed 13 fold in comparison to normal fat,
although small sample size (n = 6) must be appreciated.
As reported by Taylor et al. [123] additional deletions in
PLPS include17p13and17q11.2,where p53and thesarcoma
associated tumour suppressor gene, neuroﬁbromatosis type
1( NF-1) are located. Consistent with these observations,
Barretina et al. [116] showed 16.7% of PLPS cases had
mutations identiﬁed in p53, which are rarely seen in MLPS
and WD/DDLPS.6 Sarcoma
5.TherapeuticImplicationsinLiposarcoma
The currentmodalities available(chemotherapy,surgery and
radiotherapy) for the treatment of liposarcoma are limited,
creating a need to identify novel therapeutics.
5.1.MDM2Antagonists. Given MDM2is consistentlyampli-
ﬁed in WD/DDLPS, and sensitivity to MDM2 antagonists
(such as Nutlin-3a) is predicted by MDM2 ampliﬁcation
and an intact wild-type p53, it is an appealing therapeutic
target [40]. First generation MDM2 inhibitors work via
blockingthep53/MDM2interaction.Nutlin-3awasheralded
as one of the most promising MDM2 antagonists when it
was shown to activate wild type p53 and induce cell cycle
arrest and apoptosis in cancer cell lines [40]. These cell lines
included osteosarcoma with ampliﬁed MDM2 [40, 128].
Nutlins require wild-type p53 and a functional downstream
p53 pathway to be eﬀective [128]. M¨ uller et al. [40]s h o w e d
downstream p53 dependent transcription and apoptosis in
liposarcoma cell lines treated with Nutlin-3a [40].
Translation from in vitro to attractive in vivo therapeutic
intervention requires that drugs pass Phase I requirements.
Shangary et al. [129] designed spiro-oxindoles as a new class
of inhibitors of the MDM2-p53 complex. Spiro-oxindoles
bind to MDM2 with high aﬃnity and activates the p53
pathway, inhibiting the growth of neoplastic cell lines with
wild-type p53 [129, 130]. MI-219, the lead compound in
thisclass,demonstratesgreaterpotencyalongwithasuperior
pharmacokinetic proﬁle than Nutlin-3a [129, 131]. MI-
219 has been shown to stimulate rapid p53 activation in
tumour xenograft tissues with resultant inhibition of cell
proliferation[131].StudiesusingbothNutlin-3aandMI-219
show a p53 and p21 dependent cell cycle arrest in normal
cells, along with p53 dependent cell death speciﬁcally in
tumour cells [128, 129, 131, 132]. The ability of Nutlin-3a to
induce apoptosis in tumours is variable, and osteosarcoma
cell lines lacking MDM2 ampliﬁcation are resistant to
apoptosis [131]. Importantly, Nutlin-3a and MI-219 do not
cause visible toxicity to animals, as assessed at necropsy
[128, 129, 133].
Two oral MDM2 inhibitors have recently entered the
clinicalsetting[134],JNJ-26854165(OrthoBiotech;Johnson
& Johnson) [135] and R7112 (Hoﬀmann-La Roche) [136].
Both agents are available in advanced stage or refractory
solid tumours Phase I trials [134]. In addition, AT-219 (a
derivative of MI-219) is in preclinical studies with phase
I trials planned [134]. Of relevant interest, an MDM2
antagonist RO5045337 is about to recruit for a Phase I trial
in liposarcoma patients [137].
5.2. CDK4 Antagonists. Targeting CDK4 is an attractive
therapeutic strategy given its frequent overexpression in
WD/DDLPS [138]. A number of CDK4 inhibitors are in the
early pre-clinical development or Phase I and II trials [139].
First generation pan-CDK inhibitors include Flavopiridol
and Seleciclib (R-Roscovitine), inhibiting CDK1, CDK2,
CDK4, CDK6, CDK7, and CDK1, CDK2, CDK7 and CDK9
respectively [140]. Flavopiridol causes arrest in G1 and G2
phases in a range of solid tumour cell lines [139, 141, 142].
Flavopiridol is more potent if tumour cells are in S phase.
Matranga and Shapiro [143] demonstrated recruitment
to S phase using hydroxyurea, gemcitabine and cisplatin,
followed by ﬂavopiridol resulting in sequence-dependent
cytotoxic synergy [143–145]. Flavopiridoland Seliciclibhave
been investigated in Phase I/II trials for haematological and
solid tumours including sarcomas. Trials include Flavopiri-
dol as a single agent and in combination with taxanes
where synergism has been noted [141]. Both Flavopiridol
and Seleciclib have shown disappointing results relating to
clinical outcome and intolerable side eﬀects [146, 147].
Newer generation CDK inhibitors include PD0332991,
P27600, ZK 304709, R 547 and P1446A05. All are available
in Phase I and II solid tumour trials [146]. PD0332991
is one of two more selective CDK inhibitors speciﬁc for
CDK4 and CDK6. Preclinical data showed inhibition of
cell growth through G1 arrest in pRb-positive tumour cell
lines and antitumorigenic eﬀects in xenograft models of
colon carcinoma [148]. PD0332991 is available in Phase I
and Phase II trials for solid and haematological malignancy.
Finally, P1446A05 is the only single CDK4 selective inhibitor
available [146]. No pre-clinical data is publicly available
for this compound; however, it has been released as a
Phase I drug for refractory solid tumour and haematological
malignancies [146].
5.3. PPARγ Ligand Agonists. A critical regulator of terminal
diﬀerentiation for the adipocytic lineage is a nuclear recep-
tor peroxisome proliferator-activated receptor γ [149–151].
PPARγ is an attractive target in undiﬀerentiated lipomatous
tumours such as DDLPS and MLPS. PPARγ forms a het-
erodimericcomplexwiththeretinoidXreceptor(RXR).This
complex regulates transcription of adipocyte-speciﬁc genes
by binding sites on DNA. Agonist ligands for the PPARγ
receptor have been shown to induce terminal diﬀerentiation
of normal preadipocytes in human liposarcoma cells in vitro
[149].
A Dana-Farber Cancer Institute Phase II clinical trial
used Troglitazone, a synthetic PPARγ ligand, in patients with
high-gradeliposarcoma.Thistrialenrolledthreepatients.All
patients showed histologic and biochemical diﬀerentiation
in vivo, with reduction in immunohistochemical expression
of proliferation marker Ki-67 [149]. A more recent study
with 12 patients with Rosiglitazone, belonging to the same
class of drugs (thiazolidinediones) as Troglitazone, was not
as promising, with median progression free survival of
5.5 months. Treatment did not produce any convincing
adipocytic diﬀerentiation with no correlation between the
high expression of diﬀerentiation genes that was found in
two patients, and clinical response [152].
5.4. Trabectedin (ET-743). Trabectedin (also known as Ecte-
inascidin or ET-743) is an antitumor drug isolated from the
Caribbean marine tunicate, Ecteinascidia turbinata [153].
Trabectedin is an approved second-line agent for advanced
soft tissue sarcoma and has been shown to be exquisitely
sensitive to Trabectedin in Phase II clinical trials [154, 155].Sarcoma 7
The drug is a tetrahydroisoquinoline alkaloid whose main
mechanism of action is through binding to the DNA minor
groove with promoter and sequence speciﬁcity; however,
it has also been shown to have eﬀects on promoters that
are regulated by major groove binding transcription factors
[156–158]. Trabectedin does not appear to eﬀect transcrip-
tion of FUS-CHOP, but has been shown to dissociate the
aberrant transcription factor from promoters of its target
genes resulting in removal of the diﬀerentiation block by
activating a diﬀerentiation cascade through the C/EBPs [88].
Trabectedin relies on intact nucleotide excision repair
(NER) machinery and induces lethal DNA strand breaks
in a transcription-couple NER dependant manner [159–
161]. It has been suggested that these breaks are repaired
by homologous recombination (HR), as HR-deﬁcient cells,
such as BRCA2 mutants, are 100 fold more sensitive to
Trabectedin [162]. This eﬀect is speciﬁc to HR- mediated
double strand break repair as defects in the alternative
pathway using nonhomologous end joining do not result in
the same degree of Trabectedin sensitivity [161, 162].
FUS-CHOP modulates immune genes by activating
NF-κB controlled cytokines IL-6 and IL-8 in a C/EBPβ-
dependent manner [163, 164]. Proinﬂammatory cytokines
and growth factors such as CCL2, CXCL8, IL-6, VEGF and
PTX3 are highly expressed in both xenograft MLPS models
and patient tumours. Trabectedin has been shown to reduce
expression and production of these immune modulators,
potentially altering the tumour microenvironment in a
favorable way [165]. Thus, Trabectedin appears to aﬀect the
biological activity of FUS-CHOP and so far shows promise
as a therapeutic in MLPS.
5.5. Receptor Tyrosine Kinase Pathway Inhibitors. The high
frequency of PIK3CA and PTEN mutations suggests a
role for PI3K inhibitors in MLPS. The nonisoform-speciﬁc
PI3K inhibitors Wortmannin, and LY294002 have been
widely used in biological research but are not particularly
suited to clinical work due to their lack of speciﬁcity,
Wortmannin’s instability and LY294002’s low potency (as
reviewed [166]). GDC-0941 and PX-866 are promising
PI3K inhibitors currently in clinical trials that have low
nanomolar potency against class I isoforms of PI3K [167–
169]. In lung cancer cell lines and xenograft models,
PIK3CA mutants are more sensitive to GDC-0941 [170].
Similarly, PIK3CA mutant and PTEN-null tumours were
sensitive to PX-866 in xenograft models, and phase I clinical
trials for solid tumours are currently underway [169]. The
RapamycinderivateEverolimusinhibitsthemTORcomplex-
1( m T O R C 1 ) ,w h i c hi sad o w n s t r e a me ﬀector of PI3K.
Both H1047R and E545K PI3K mutant cells are sensitive
to Everolimus [171]. PIK3CA mutated MLPS represents an
ideal candidate for PI3K inhibition.
As MET is activated in MLPS and there are many
MET pathway inhibitors currently in development and in
clinical trials (as reviewed in [172], MLPS may be a good
candidate for MET inhibition. For example, the novel and
promising inhibitor Foretinib (XL880) inhibits multiple
kinases including both MET and VEGFR2 and exhibits
extensive biological activity and clinical eﬃcacy in an early
Phase I clinical trial in metastatic or unresectable solid
tumours [173].
6.Conclusion
Molecular-based therapeutics are not routinely used in
liposarcoma, where surgery, radiotherapy, and chemother-
apyremainthemainstayoftreatment.Translationoftargeted
molecular therapeutics in sarcoma has been successfully
demonstrated with Imatinib mesylate therapy in c-Kit pos-
itive gastrointestinal stromal tumour (GIST) [174]. A major
challenge with the use of molecularly targeted therapeutics
is to translate disease control into disease eradication. One
strategy to achieve this goal is to combine two or more inde-
pendent molecularly targeted agents in a disease where all
of the targets are relevant. The dependence of WD/DDLPS
on ampliﬁcation of both MDM2 and CDK4 means that this
disease represents an important candidate for combination
therapy. Recent studies point towards RTK involvement
in MLPS oncogenesis, particularly signaling through the
PI3K/Akt pathway. This provides an important avenue for
new research due to the large number of clinical trials
currently underway that target this pathway. Although not
considered a molecularly targeted therapeutic, treatment of
MLPS with Trabectedin iscurrentlyin latestage clinicaltrials
with promising results.
It is hoped that emerging technologies, such as next-
generation sequencing, will be fundamental in revealing
new molecular targets in liposarcoma. Similarly, advances in
drug development should enable improvement of molecular
therapies with greater sensitivity, speciﬁcity, potency, and
limited toxicity. Combining technologies in both areas will
allow for eﬃcient clinical translation.
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